Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses - add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty

Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Natalizumab (Tysabri) for secondary progressive multiple sclerosis. Birmingham: NIHR Horizon (...) Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Natalizumab (Tysabri) is intended for the treatment of secondary progressive multiple sclerosis (SPMS) in patients who have progressed from relapsing remitting MS. If licensed, natalizumab will offer an additional treatment option for patients with SPMS, a group who currently have few effective therapies available. No disease-modifying drugs are currently licensed specifically for SPMS. Natalizumab is a selective

Masitinib for primary and relapse-free secondary progressive multiple sclerosis - first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Masitinib (...) for primary and relapse-free secondary progressive multiple sclerosis – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Masitinib is intended to be used as first line therapy for the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis. If licensed, masitinib will offer a novel, oral treatment option for this patient group for whom no licensed therapies are currently available. Masitinib

Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis Article Text Therapeutics/Prevention Randomised controlled trial Cannabinoids fail to show evidence

Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14 (...) ? Sarah Mostardt ? Katrin Nink ? Sibylle Sturtz ? Beate Wieseler ? Min Zhou Keywords: dimethyl fumarate, multiple sclerosis – relapsing-remitting, benefit assessment 2 Due to legal data protection regulations, employees have the right not to be named. Extract of dossier assessment A14-14 Version 1.0 Dimethyl fumarate – Benefit assessment acc. to §35a Social Code Book V 30 July 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List

Daclizumab High Yield Process for relapsing forms of multiple sclerosis ? first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanizeds; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting Language Published English Country of organisation England English summary An English language summary is available. Address

Ocrelizumab for relapsing-remitting multiple sclerosis Ocrelizumab for relapsing-remitting multiple sclerosis Ocrelizumab for relapsing-remitting multiple sclerosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Ocrelizumab for relapsing-remitting multiple sclerosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Humans; Multiple Sclerosis, Relapsing-Remitting Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831

Ocrelizumab for primary progressive multiple sclerosis Ocrelizumab for primary progressive multiple sclerosis Ocrelizumab for primary progressive multiple sclerosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Ocrelizumab for primary progressive multiple sclerosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Multiple Sclerosiss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc

Dimethyl fumarate for treating relapsing-emitting multiple sclerosis Dimeth Dimethyl fumar yl fumarate for treating ate for treating relapsing-remitting multiple sclerosis relapsing-remitting multiple sclerosis T echnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 59Contents Contents 1 Guidance 4 2

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients (...) with relapsing-remitting multiple sclerosis.We did this 2-year, double-blind, parallel group, phase 3 study, with a placebo-controlled design for the first 48 weeks, at 183 sites in 26 countries. Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks

Teriflunomide - Multiple Sclerosis, relapsing Common Drug Review CDEC Meeting — May 21, 2014 Notice of Final Recommendation — June 18, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION TERIFLUNOMIDE (Aubagio — Genzyme Canada) Indication: Relapsing-Remitting Multiple Sclerosis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that teriflunomide not be listed at the submitted price. Reasons for the Recommendation: 1. Two randomized controlled trials (RCTs) (TOWER (...) and TEMSO) demonstrated that the annualized relapse rate was lower with teriflunomide compared with placebo for patients with relapsing-remitting multiple sclerosis (RRMS) and one RCT (TENERE) demonstrated no statistically significant difference in the annualized relapse rate between teriflunomide and interferon beta-1a. 2. At the submitted price, teriflunomide ($vvvvvv per year) is more costly than glatiramer acetate ($16,241 per year) and interferon beta-1b (Extavia) ($18,133 per year). CDEC concluded

Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya) Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°)'', 1 January 2014 {1} {1} {1} | | > > > Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Multiple sclerosis: monitor for the cardiac risks of fingolimod (Gilenya°) Starting a treatment with fingolimod, or resuming it after a break, exposes the patient to excessive slowing of the heart rate and requires close cardiac monitoring for several hours. Fingolimod is authorised for the treatment of multiple sclerosis in patients who do not respond to beta interferon therapy, or who have a severe, rapidly progressing disease. Compared with beta interferon treatment, fingolimod appears to reduce

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial Patients who develop relapsing-remitting multiple sclerosis (MS) present with a first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 study we investigated the effect of oral cladribine on conversion to clinically definite MS in patients with a first clinical demyelinating event, when

Information provision for people with multiple sclerosis. People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. Among others, these include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies and non-pharmacological interventions. It has been shown that people with MS demand adequate information to be able to actively participate in medical decision making and to self-manage (...) to promote informed choice and improve patient-relevant outcomes.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register which contains trials from CENTRAL (The Cochrane Library 2013, Issue 6), MEDLINE, EMBASE, CINAHL, LILACS, PEDro and clinical trials registries (12 June 2013) as well as other sources. In addition, we searched PsycINFO, trial registries, and reference lists of identified articles. We also contacted trialists.Randomised

A systematic review of pharmacological pain management in multiple sclerosis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases such as active relapsing-remitting (RRMS) and progressive MS.To assess (...) the efficacy and safety of MMF for preventing disease activity in patients with RRMS.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (January 14, 2013). We searched three Chinese databases (January 2013) and checked reference lists of identified trials. We contacted authors and pharmaceutical companies to ask for additional information. We applied no language restrictions.We included randomized controlled trials with a follow-up

An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial To examine the efficacy of the modified Story Memory Technique (mSMT), a 10-session behavioral intervention teaching context and imagery to facilitate learning, to improve learning and memory abilities in persons with multiple sclerosis (MS).This double-blind, placebo-controlled, randomized clinical trial included 86 participants with clinically definite MS, 41 in the treatment group and 45 in the placebo control

Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatment of patients with multiple sclerosis: a review of guidelines (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Limited evidence-based guidelines are available for the treatment of multiple sclerosis, and the stopping or switching of treatment. The available evidence has suggested plasmapheresis as an adjunctive or alternative treatment for MS, corticosteroids for the treatment of relapse, and natalizumab in cases of failure on other drugs or intolerance. Final

Teriflunomide for treating relapsingûremitting multiple sclerosis (TA303) Overview | Teriflunomide for treating relapsing–remitting multiple sclerosis | Guidance | NICE Teriflunomide for treating relapsing–remitting multiple sclerosis Technology appraisal guidance [TA303] Published date: 22 January 2014 Last updated: 01 June 2014 Share Guidance on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults. Guidance development process Next review : When the review

Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312) Overview | Alemtuzumab for treating relapsing‑remitting multiple sclerosis | Guidance | NICE Alemtuzumab for treating relapsing‑remitting multiple sclerosis Technology appraisal guidance [TA312] Published date: 28 May 2014 Share Guidance on alemtuzumab (Lemtrada) for treating relapsing–remitting multiple sclerosis in adults. Guidance development process Next review: We will decide whether to review this guidance when